Abstract: The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.

Abstract: The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.

Abstract: The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.

Abstract: The present disclosure provides a truncated Evans Blue modified fibroblast activation protein inhibitor compound. The compound is formed by connecting truncated Evans Blue, a fibroblast activation protein inhibitor and a nuclide chelating group by means of connecting groups L1, L2, L3, L4 and X. The compound has the following structure shown in Formula (I), where R1 is a fibroblast activation protein inhibitor; L1 is lysine, glutamic acid, or a derivative structure thereof; L2 is —(CH2)n—, n is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; L3 is —(CH2)m—, m is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O— or —(CO)—; L4 is —(CH2)p—, p is an integer from 0 to 30, and each —CH2— may be individually substituted or unsubstituted with —O—, —NH—, —(CO)—, —NH(CO)—, or —(CO)—NH—; X is selected from N, C, O, S, or and R2 is a nuclide chelating group.

Abstract: The present invention relates to formulations of radiolabelled compounds that are of use in radiotherapy and diagnostic imaging.

Abstract: A compound of general formula I Also, the use of the compound for the complexation of a metal ion, including lutetium ions or actinium ions, and the method for the complexation of a metal ion in which the compound is contacted with the metal ion at a reaction temperature in the range of from 20 to 50° C.

Abstract: Combination therapies comprising administering radioimmunoconjugates and one or more checkpoint inhibitors.

Abstract: The present disclosure provides a composition that includes a mixture of (i) radioactive microparticles; and (ii) non-radioactive microparticles. The radioactive microparticles may be suitable to treat a vascularized tumour, such as a liver tumour or a metastasized liver tumour. The radioactive microparticles and the non-radioactive microparticles may have substantially the same resistance when flowing in a liquid through a conduit. The present disclosure also provides methods of making and methods of using mixtures of microparticles.

Abstract: A substance which regulates immune-checkpoints for use as a medicament for treatment of a tumor of a patient wherein the administration pattern of the medicament comprises administering a therapeutically effective amount of the substance to the tumor, in one or more sessions, and implanting seeds (204) carrying radium-224 in the tumor for intra-tumoral alpha-emitter radiotherapy less than two weeks from administering the substance.

Abstract: A system for treating plant material uses a vessel capable of being brought to a vacuum and/or pressurized and maintained at a relatively low temperature. Plant material is placed within the vessel and the vessel draws a vacuum or is pressurized. A control system may monitor and control the creation of a vacuum, flow rate of a gas from a gas tank into the vessel, the temperature in the vessel, the flow rate of gas out of the vessel, and the pressure of the vessel.

Abstract: A handheld light assembly for eradicating pathogens includes a housing. A processor and a lamp are disposed inside the housing. The lamp irradiates surfaces with disinfecting ultraviolet light having a peak wavelength of 222 nm filtered to restrict illumination to between 200 nm and 230 nm within an irradiation zone. A distance measuring system includes a secondary light source generating secondary light and a photodetector for measuring distance of the secondary light to a surface being irradiated by the lamp light being reflected from the surface to the photodetector. The secondary light source is offset at an angle from the lamp thereby projecting the light beam to a central area of the irradiation zone generated by the lamp. The photodetector signals the processor to calculate a vertical distance between the lamp and the central area of the irradiation zone on the surface being irradiated from an angular projection of the secondary light.

Abstract: A method for decontaminating a closed space, comprising providing a reservoir of a cleaning fluid; generating a very dry mist comprising cleaning fluid comprising aerosol droplets, wherein the mist is subjected to a nonthermal plasma actuator to form plasma activated ionic particles carried by the aerosol droplets of the mist, wherein the plasma activated ionic particles are hydroxyl ions; wherein a flow meter monitors a flow of the mist through a self-cleaning nozzle into the closed space, and wherein the flow rate of the mist through the self-cleaning nozzle is not greater than 2 ml/min; wherein air pressure within the closed space is maintained as neutral; wherein there is no cavity permitted within the self-cleaning nozzle other than that through which the very dry mist flows, wherein the generated very dry mist is applied to decontaminate the closed space.

Abstract: An enclosed structure for receiving fog from a fog-producing device. The fog comprises fog particles of water and an active substance that is capable of being aerosolized. A plurality of spaced-apart redirector surfaces is located within the enclosed structure; these surfaces define flow paths for the fog to travel. The fog particles collide with or pass proximate the redirector surfaces, causing the larger fog particles to fall out of the fog flow path, while the smaller fog particles continue along the fog flow path, finally exiting the enclosed structure. After exiting, the fog particles strike a target, with the active substance within the fog particles treating the target.

Abstract: An apparatus for delivering a virus action suppressing component performs, when delivering an active ingredient including a virus action suppressing component into a space, detecting a humidity in the space, determining whether the humidity in the space is equal to or higher than a first set value, and increasing an amount of the active ingredient delivered into the space when the humidity in the space is equal to or higher than the first set value, compared to when the humidity in the space is less than the first set value. This can increase the effect of suppressing the action of viruses when the humidity is high.

Abstract: A purification and sanitization device (1) is provided, comprising a duct (2) developing along a development trajectory (2a) between an inlet (20) designed to allow air from an external environment into said duct (2) and an outlet (21) designed to allow the exit of air from the duct (2) to an external environment; a first photocatalytic stage (3) including a first plate (30) made of porous nano- or micro-ceramics enriched with titanium dioxide and apatite and placed in the duct (2) transversely to the development trajectory (2a), a first light emitter (31) configured to emit a first UV-C light in such a way that the first light can strike said first plate (30) and to vary, on command, the wavelength of the first light at least between 250 nm and 390 nm with a tolerance of ±10 nm; a second photocatalytic stage (4) including a second plate (40) made of tungsten trioxide and placed in the duct (2) between the first plate (30) and the outlet (21) transversely to the development trajectory (2a), a second light emi

Abstract: Described herein are oxygen-enriched tamponade compositions comprising silicone oil or a perfluorocarbon and methods of their use in the repair of retinal detachment. Post-operative repair for retinal detachment can include enhanced wound healing as the result of the administration of the compositions described herein. The enhanced wound healing can include rescue of ischemic retinal tissue, surgery induced hypoxia, and reduction of unwanted scar tissue development and prevention of re-detachment of the retina after surgical repair.

Abstract: The present invention relates to a composition using a fiberized acellular dermal matrix and a method of preparing the same and, more particularly, to a composition using a fiberized acellular dermal matrix prepared without addition of a biocompatible polymer and a method of preparing the same.

Abstract: The present disclosure provides fasciculated nerve grafts of customizable lengths and diameters, and methods of preparing the same. The grafts are made by digesting native extracellular matrix (ECM) around the nerve fascicles of a nerve tissue, and the epineurial sheath. One or more of the individual fascicles may then be entubulated in an entubulation material, embedded in or coated with a coating material, or both, to form a fasciculated nerve graft. The fasciculated nerve grafts are customizable and designed to bridge nerve gaps; the modularity of the fasciculated nerve graft allows for restoring continuity to nerve defects of virtually any length and allows for matching the diameter of the patient's recipient nerve.

Abstract: An embodiment includes therapeutic compositions that include a hydrogel medium and a plurality of tissue segments dispersed within the medium. The hydrogel medium preserves and stores the tissue through processing, transport, and storage. The embodiment addresses an identified problem of preserving a tissue, whether such tissue is fresh, cryopreserved, or sterile. The therapeutic compositions may be placed on or within the body to cover and protect wounds, provide a scaffold for reconstruction, repair, or replacement, and reduce surgical complications as a result of inflammation and scar tissue formation. Other embodiments are described herein.

Abstract: The present disclosure describes the use of immune modulators to promote nerve growth and regeneration, particularly in the context of nerve deficit stemming from trauma and disease. In particular, the disclosure provides for the use of CXCR4 antagonists, STAT3 activators, and an agent that increases levels of nitric oxide, either alone or in any combination of these drugs, in surgery performed to treat nerve deficit conditions, especially peripheral nerve deficit conditions caused by cut injury or tear injury, the method especially useful in bridging nerve gaps of 3 cm or longer.

Abstract: The present disclosure relates to a scaffold with atelocollagen inserted into a porous hyaluronic acid polymer for treatment and recovery of tendon or ligament diseases. The scaffold enhances the efficacy of hyaluronic acid and atelocollagen through slow and prolonged secretion at the suture site, thereby creating a synergistic effect. Additionally, the porous scaffold with high mechanical properties binds the suture site of a ruptured tendon and provides a microenvironment for the regeneration process of surrounding cells, thereby making it useful for the treatment and recovery of tendon or ligament diseases.

Abstract: The present invention provides a thin-walled PTFE tube with appropriate elongation, sufficient strength, and good uniformity during stretching and a medical tube with excellent flexibility and dimensional accuracy. The polytetrafluoroethylene tube according to the present invention is a polytetrafluoroethylene tube having a wall thickness of about 0.04 mm or less, wherein the wetting tension of either of or both outer and inner surfaces of the polytetrafluoroethylene tube is 46 mN/m or more, and in a stress-strain curve obtained by a tensile test performed under an atmosphere of 200° C., tensile stress at 20% strain ?20 (N/mm2) of the polytetrafluoroethylene tube and tensile stress at 50% strain ?50 (N/mm2) of the polytetrafluoroethylene tube satisfy 2.0?0.1×?20+0.3×?50<5.5 (Inequality (1)).

Abstract: Compositions comprised of oxidized cellulose (OC) in the form of a powder, wherein the carboxyl content of the OC is about 9% to about 18%, by weight, are disclosed. Optionally, the powder is in an aggregated form. Uses of the compositions for preventing tissue adhesion in the presence of bleeding are further disclosed.

Abstract: A breast pump shaped at least in part to fit inside a bra and comprising a housing including an aggregate, a breast shield element including a nipple tunnel adapted to receive a nipple, and a milk container adapted to contain a predetermined amount of expressed milk, wherein the breast shield element and the milk container are detachable from the housing. The present invention proposes an aggregate including a piston adapted to reciprocate within the housing, which piston moves the membrane. In the method expressed milk flows from a nipple chamber, which when the breast shield element is laid against a breast is defined in the nipple tunnel between a free end of the nipple tunnel and the breast, through the milk outlet valve into the pumping chamber and from the pumping chamber through the container valve into the milk chamber.

Abstract: A hemodialysis system is disclosed. The hemodialysis system includes a dialyzer and an online dialysate generation system comprising a water inlet line and a drain line. The hemodialysis system also includes a disposable set comprising a supply tube fluidly connected to online dialysate generation system and a dialysate pumping tube fluidly connected to the dialyzer. The hemodialysis system further includes a dialysis instrument comprising a dialysate pump head and a motor positioned and arranged to operate the dialysate pump head. The dialysis instrument operates the dialysate pump head to move fresh dialysate from the online dialysate generation system through the dialysate pumping tube to the dialyzer.

Abstract: A medical device includes regions, components located in the regions, and a control unit. The control unit determines a state of the medical device, at least one component that is related to the state of the medical device, and display items derived from the state of the medical device and concerning the at least one determined component. A display unit simultaneously displays the display items. The display items include a detail view area with a representation of the at least one component, and an information area with information related to the state of the medical device and concerning the at least one component. The display items also include an overall view area with sub-areas that are representations of regions of the medical device. At least one of the sub-areas indicates in which region the at least one component is located. The medical device is controlled by a control method.

Abstract: An artificial lung system for a patient having a membrane lung system having an gas inlet, a blood inlet, a blood outlet, and an exhaust; a gas system operably coupled to the gas inlet of the membrane lung system; a gas phase sensor disposed downstream of the exhaust of the membrane lung system and monitoring an exhaust gas levels; and a feedback controller receiving the blood CO2 or O2 signal and outputting a control signal to control gas flow and/or blood flow.

Abstract: Described herein are compositions and methods for performing plasmapheresis. The compositions and methods for performing plasmapheresis are innovative at least in their application towards the treatment and prevention of aging and conditions associated with aging. Plasmapheresis compositions and methods described herein are directed towards reducing or eliminating conditions associated with aging.

Abstract: Filtering device for filtering cerebrospinal fluid are disclosed. An example filtering device may include a filter housing having an inlet for receiving cerebrospinal fluid from a patient and an outlet for returning filtered cerebrospinal fluid to the patient. The filter housing may include a plurality of layers coupled together and defining a fluid pathway therein between the inlet and the outlet. A filtering section may be defined within the filter housing along the fluid pathway. The filtering section may include a widened region of the fluid pathway that is configured to slow the passage of fluid therethrough.

Abstract: Method for maintaining blood substantially free of biochemical coagulation and/or particulate precipitation during extracorporeal treatment of blood. A volume of blood is introduced into a blood container moved in a rotary orbital motion using an orbital vortex motor to generate a sinusoidal wave in the moving blood, thus establishing a laminar flow of the blood in the blood container and over a blood-contacting surface. The blood may be introduced using an intravenous (IV) tube from a vein of a patient, and applying suction pressure to a port of the blood container. An ozonation device may be used to introduce a mixture of oxygen and ozone into the blood container during continued rotary orbital motion. A subsequent positive pressure can be applied to return the blood to the patient. Multiple passes can be performed in succession. Compounds such as anti-coagulant agents may be administered or omitted as required.

Abstract: A drainage system for draining bodily fluid from a body cavity includes a fluid-receiving body having a fluid-receiving chamber located therein that receives a bodily fluid through an inlet. An actuation body is connected to the fluid-receiving body. The actuation body includes an actuation member that is accessible from outside the actuation body and is manually movable relative to the actuation body along a dimension of the actuation body. The actuation member is operatively connected to a suction inducing member. Manual actuation of the actuation member relative to the actuation body moves the suction inducing member thereby increasing a volume of a suction chamber and reducing a pressure within the suction chamber. The reduced pressure communicated through the inlet of the fluid-receiving body.

Abstract: A real-time fluid drainage monitoring and control system, method, and device are disclosed, wherein the system is portable, standalone, and can be networked to local and global servers, and is amenable to operation for different medical needs including, but not limited to, external ventricular drain (EVD), external lumbar drain (ELD), and urine output (UO) monitoring and management.

Abstract: Embodiments of apparatuses and methods for providing negative pressure wound therapy to multiple wounds are disclosed. In some embodiments, presence of blockage in one or more fluid flow paths connecting a negative pressure source to one or more dressings can be performed. Determination of a blockage can be performed based on comparing one or more pressure measurements to at least one threshold. The at least one threshold can be determined based on detected capacities of the one or more dressings.

Abstract: A negative pressure wound therapy system can include a negative pressure source configured to provide, via a fluid flow path, negative pressure to a wound covered by a wound dressing. The system can include a controller. The controller can be configured to periodically activate the negative pressure source to maintain negative pressure in the fluid flow path between a low negative pressure setpoint and a high negative pressure setpoint. The controller can be configured to determine a change in a volume of the wound based on a difference between a first time and a second time at which the high negative pressure setpoint has been established in the fluid flow path, the second time being subsequent to the first time. The controller can be configured to provide indication of the change in the volume of the wound.

Abstract: A thrombectomy system includes a catheter having a proximal end and a distal end, a valve in fluid communication with the catheter, and a cutting instrument associated with the distal end of the catheter. The cutting instrument may be configured for axial and/or rotational motion. A controller of the system may be configured to detect operational parameters of the cutting instrument. The controller may determine whether the cutting instrument is engaging with occlusive material based on the detected operational parameters. The controller may operate the valve in one or more operating modes to alter a level of pressure in the catheter based on whether the cutting instrument is engaging with the occlusive material.

Abstract: The approaches described herein can provide mitigation against the risk of one or more malfunctions of electronics of a negative pressure wound therapy device. The one or more malfunctions can include flow reverse current, flow of excessive current, liquid ingress, or inadvertent activation. The approaches described herein can provide protection against a single fault (or higher protection against more than one fault). Advantageously, mitigation against the risk of burning or otherwise causing discomfort to the patient or the risk of fire can be provided.

Abstract: An apparatus for applying negative pressure to a wound is disclosed. The apparatus can include a housing, a pressure source, a canister, and a controller. The pressure source can be supported by the housing and provide negative pressure via a fluid flow path to a wound dressing positioned over a wound. The canister can collect exudate from the wound. The controller can monitor a parameter indicative of providing negative pressure to the wound dressing with the pressure source, determine from the parameter that the wound is treatable with a canisterless wound therapy apparatus, and output for presentation to a user a notification indicating that the wound is treatable with the canisterless wound therapy apparatus.

Abstract: In one embodiment a system to monitor an analyte and dispense an infusate is disclosed. The system includes an on-body assembly with a first piece and a second piece. The first piece contains a sensor and a cannula and the cannula is in fluid communication with a first piece fluid channel. The second piece contains a pump mechanism connected to a second piece fluid channel. When the first piece is coupled to the second piece, the first piece fluid channel is placed in fluid communication with the second piece fluid channel to establish fluid transport from the pump mechanism through the cannula.

Abstract: A drug infusion device with elastic anti-reverse member includes an infusion mechanism module, a control mechanism module, and an adhesive patch. The infusion mechanism module includes a reservoir used for accommodating the drug to be infused, a driving wheel assembly, a driving unit with a driving end that pushes the driving wheel to rotate, a power unit and a reset unit. The driving wheel assembly includes a driving wheel, a driving tube and a cover. The cover is used to fix the driving wheel and also provided with at least one elastic member abutting against the driving wheel assembly. The power unit and the reset unit are connected with the driving unit. The power unit exerts a force on the driving unit to make the driving wheel move forward, and the reset unit exerts a force on the driving unit to reset the driving end.

Abstract: A skin patch drug infusion device includes: a control mechanism module and an infusion mechanism module. The infusion mechanism module includes a reservoir, a piston and a screw. A driving unit includes one rotating shaft and at least one driving member, and the driving member includes one driving end, the driving member can rotate around the rotating shaft to advance or reset the driving end. At least one driving wheel is provided with wheel teeth, and the advancing driving end can push the wheel teeth to rotate the driving wheel, thereby driving the screw forward. A linear actuator and a reset unit are respectively connected to the driving member, the linear actuator and the reset unit are respectively apply driving power to the driving member to advance and reset the driving end.

Abstract: Devices, systems, and methods for detecting a fluid infiltration event. A system includes a fluid delivery cannula having a distal end and a proximal end, a fluid source fluidly coupled to the proximal end of the fluid delivery cannula, and an optical sensor optically coupled to an interior of the fluid delivery cannula. The optical sensor is disposed between the distal end and the proximal end of the fluid delivery cannula and configured to generate an electronic signal based on one or more characteristics of light sensed in the interior of the fluid delivery cannula when fluid from the fluid source is passed therethrough. The system further includes a controller configured to receive the electronic signal from the optical sensor and determine a fluid infiltration event based on the electronic signal.

Abstract: An example device for detecting intravenous (IV) infiltration by identifying leaks and swelling at the patient skin. The device uses skin swelling to displace alignment of overlapping layers to produce a pattern or indication of swelling. Leakage is detected through the use of a conduit to wick liquid away from an insertion site and react with a dye or reagent to produce a color change that makes a clear visible indication of leaking. The detection methods provide visible markers without occluding visibility of the insertion site for the IV therapy.

Abstract: A CSF management method is used with a patient having a body with CSF having a natural flow rate. The method determines determining a target volume for a CSF-containing target compartment of a patient from a volumetric image. The method determines a personalized therapeutic infusion volume of a therapeutic material as a function of the target volume and a total therapeutic infusion volume. A CSF circuit is formed to control flow of CSF in the body. The personalized therapeutic infusion volume is added to the CSF via the CSF circuit at a first time. The therapeutic material is directed, via the CSF, toward the target compartment of the patient. The flow of the CSF in the CSF circuit is adjusted to localize the CSF at the target compartment of the patient.

Abstract: Techniques disclosed herein relate to continuous analyte sensor quality measures. In some embodiments, the techniques may involve obtaining a sensor-generated value that is indicative of a physiological characteristic of a user of a medical device. The techniques may further involve causing, in response to obtaining a sensor quality metric that indicates accuracy of the sensor-generated value, configuration of a quality-specific operating mode of the medical device, the quality-specific operating mode comprising regulation of basal and bolus deliveries of a fluid medication based on the obtained sensor quality metric.

Abstract: A drug delivery device includes an upper housing shell, a lower housing shell, and a syringe. The syringe includes a barrel, a stopper, and a needle, at least a portion of the syringe positioned within the lower housing shell. The drug delivery device further includes a drive assembly including a plunger body configured to move the stopper within the barrel upon actuation of the drive assembly, a cassette body configured to receive the syringe, and a motor body configured to engage the cassette body. The motor body includes a pair of sidewalls and a contact surface provided on each of the pair of sidewalls. The contact surface engages a corresponding contact surface of the cassette body.

Abstract: An injection device assembly including a housing, a syringe, a drive mechanism and one or more sensing systems are described. The drive mechanism advances the syringe from a storage position to an injection position, and a plunger advances the syringe piston from an initial position to a final position. The status sensing system may include one or more main PCB(s) disposed in an end portion of the injection device assembly's housing. The system may determine various parameters related to an operational status of the injection device, including the location of the device's components, an amount of medication remaining in the device, a temperature of the medication, and whether or not the device is properly contacting the user's skin before injection. The system may communicate such determined parameters to an external device via a wireless communication link.

Abstract: A medicament delivery system is described. Embodiments of the medicament delivery system can include a smart user device and a smart medicament delivery assembly. The smart medicament delivery assembly can be implemented as a single-use cartridge that can be removably coupled to the smart user device. The smart user device can be configured to determine when to automatically administer a medicament stored in the smart medicament delivery assembly by receiving data from the smart medicament delivery assembly.

Abstract: The invention relates to a pre-filled single dose injection device expelling one single dose of a predetermined fixed volume with an embedded cartridge wherein a piston rod has a predetermined travel distance and wherein the position of the travel distance of the piston rod relatively to a housing structure securing the cartridge is individually adjustable for each individual injection device.

Abstract: Examples of the present application disclose a medication delivery apparatus comprising a first plunger, a second plunger and a container configured to receive the second plunger and at least a portion of the first plunger. The container and the second plunger define a dilution chamber that is configured to receive a diluent. The container defines a dilution chamber opening. The first plunger, the container and the second plunger define an active agent chamber that is configured to receive a pharmaceutical preparation. The second plunger comprises a one-way valve configured to control a flow of pharmaceutical preparation from the active agent chamber to the dilution chamber. The one-way valve is configured to move from a closed position to an open position upon application of a force exceeding a valve threshold force to an inlet side of the valve. The valve threshold force is less than a sum of a break loose force of the second plunger and a break loose force of the first plunger.

Abstract: A syringe and syringe package system comprises a syringe barrel having an open proximal end and a distal end and a syringe stopper placed in the open proximal end of the syringe barrel. The system includes a shape-changeable package, the syringe barrel and the syringe stopper contained within the shape-changeable package, wherein the shape-changeable package comprises a web of material sized and arranged to contain the syringe barrel and the syringe stopper and configured to be converted to a plunger rod that engages the syringe stopper and is translatable within the open proximal end of the barrel.